Going beyond the population of patients with high-risk localized PCa, we propose that the AR activity–low population of metastatic hormone-sensitive PCa that would otherwise show poor response to enzalutamide may be targeted by HER2 inhibition, a hypothesis that could be readily tested in a genomically guided adjuvant therapy clinical study. The gene discussed is ERBB2; the disease is posterior cortical atrophy.